All News
CDC: Chronic Fatigue Syndrome 2021-2022
The current CDC report estimates that 1.3% of adults had myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), based on the most recent population based National Health Interview Survey (NHIS 2021–2022).
Read Article
ICYMI: Cancer and TNF inhibitors
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.
Read Article
ICYMI: Urinary biomarkers precede loss of kidney function for lupus nephritis
In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation.
Read Article
Hemophagocytic Lymphohistiocytosis in Still's disease Dr. Bella Mehta discusses abstract 1143, presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/AFoKm6kT86 https://t.co/dLTjTOdbmv
Dr. John Cush RheumNow ( View Tweet)
Watch: Non-TNFi b/tsDMARDs vs. TNFi in RA-ILD
https://t.co/fOz4jH58r9 https://t.co/jSHnsZscPg
Dr. John Cush RheumNow ( View Tweet)
Cardiology 101 for the Rheumatologist
Dr. Janet Pope reports on a cardiology session presented a 2023 ACR Convergence in San Diego, CA
https://t.co/0cS8JVneIG https://t.co/6SIPx6WmqX
Dr. John Cush RheumNow ( View Tweet)
FDA Warning on CAR-T Cell Therapy
The FDA issued a safety alert on CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
https://t.co/1OiMWJMskz https://t.co/8i8LFMcb1s
Dr. John Cush RheumNow ( View Tweet)
Full read BMJ ovverview of PMR
- PMR Clinically recognized 1957
- Is it a uniquie vs overlap entity
- Is there subclinical GCA in PMR?
- Is PMR for PCPs?
https://t.co/0BKGdt5Kxf https://t.co/sfAZoYyVan
Dr. John Cush RheumNow ( View Tweet)
ICYMI: How early is early in PsA?
Guidelines for the management of PsA recommend the early referral of patients with the suspected condition for early assessment and treatment.
https://t.co/AAZegiV6OL https://t.co/v5jIsPjX0c
Dr. John Cush RheumNow ( View Tweet)
Subtype of dermatomyositis is positive for Melanoma differentiation-associated protein 5 (MDA5) antibody. This poor prognosis subtype has distinctive rashes, rapidly progressive interstitial lung disease, lymphopenia &elevated ferritin levels https://t.co/FJjdO27cQQ https://t.co/gis2aWOLa7
Dr. John Cush RheumNow ( View Tweet)
Early bird pricing has been extended! Register today!
https://t.co/BysC0RunUh https://t.co/4Ar0kHa4tt
Links:
Dr. John Cush RheumNow ( View Tweet)
Palmoplantar pustulosis (PPP) is difficult to treat; w/ few reports of JAKi efficacy. Now a report of 21 PPP pts given bimekizumab and 17 patients showed complete clearance in 1 to 4 months. SAPHO pts had complete clearance of skin & improved joint pain https://t.co/tYpHCxFOBI https://t.co/i4o3KnGlPY
Dr. John Cush RheumNow ( View Tweet)
UK Dermatology Registry of 13 699 Psoriasis pts on biologics (25K biologic exposures) found 1% risk of paradoxical eczema. Biologics included inhibitors of TNF, IL-17, IL12/23, IL-23. Lowest risk w/ IL-23i (0.56/100kPY), and higher w/ IL-17i (1.22) https://t.co/fOX6VGJQLk https://t.co/u1p1sidCte
Dr. John Cush RheumNow ( View Tweet)
Post-Menopausal Osteoporosis Review and Recommendations
A recent New England Journal review of post-menopausal osteoporosis (OP) provided updated information, strategies and a review of guidelines and clinical recommendations.
https://t.co/TkJjsX98Ww https://t.co/2Hi72GjEHM
Dr. John Cush RheumNow ( View Tweet)
ICYMI: The Heart of Lupus
Few people are aware of the EULAR recommendations1 for cardiovascular (CV) risk management in systemic lupus erythematosus (SLE) published in 2022. The recommendations had 4 overarching principles...
https://t.co/5I5eYNqHIu https://t.co/W6VzUFs6kN
Dr. John Cush RheumNow ( View Tweet)
Withdraw DMARDS after remission?
Considering withdrawing DMARDs after remission is on our minds. When patients inquire about tapering or stopping DMARDs while doing well, we often lack a clear-cut answer.
https://t.co/wqcCff7kjx https://t.co/vq9ee1dZNX
Dr. John Cush RheumNow ( View Tweet)
Calcineurin Inhibitors in Lupus Nephritis
Dr. Kathryn Dao discusses abstract 1509 with Dr. Gabriel Figueroa-Parra at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/1sjvCUyvD9 https://t.co/kocmtM1j6o
Dr. John Cush RheumNow ( View Tweet)
Pneumocystis Jiroveci Pneumonia (PJP) Risk
https://t.co/OTG9Ud1adu https://t.co/jIhdwws0Un
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Are Rheumatologists doing Enough for Cervical Cancer?
https://t.co/afg5YL3RCN https://t.co/VRyKh6VgmS
Dr. John Cush RheumNow ( View Tweet)
Even low-dose, short-term steroid use increases the risk of serious CV events
Dr. Meral El Ramahi (Nashville, TN) reports on abstract 2430 presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/apgxXeVw1U https://t.co/zPiUCqtJlf
Dr. John Cush RheumNow ( View Tweet)
